Clovibactin

Natural product antibiotic
2023
  • Development status: Experimental

  • Gram-positive activity

  • Gram-negative activity

  • Mechanism of Action/Target pathogen: Active against methicillin-resistant <i>Staphylococcus aureus</i>, daptomycin-resistant <i>Staphylococcus aureus</i>, vancomycin-intermediate <i>Staphylococcus aureus</i>, vancomycin-resistant <i>Enterococcus</i>, and <i>Haemophilus influenzae S</i>J7; binds to pyrophosphate moiety of C55PP, lipid II, and lipid IIIWTA

  • Additional information: Natural product from 'uncultured' soil bacteria <i>Eleftheria terrae ssp. Carolina; </i>no cytotoxic activity towards NIH/3T3 and HepG2 mammalian cells at 100 mg/L (highest tested vs MIC at 0.125 to 2 mg/L)

  • GtoPDB link: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=13080
  • Source: https://www.cell.com/cell/fulltext/S0092-8674(23)00853-X